New guidance released on genetic testing for dyslipidemia patients

By The Science Advisory Board staff writers

July 17, 2020 -- The National Lipid Association (NLA) has released a scientific statement on the use of genetic testing in the diagnosis and management of patients with dyslipidemia.

The statement provides information for healthcare providers on genetic testing, including risks and benefits, as patients may require testing to help confirm a diagnosis or guide therapy.

The statement discusses the importance of genetic counseling before and after genetic testing and outlines potential limitations of testing in dyslipidemia. It also has a detailed table of recommendations to guide healthcare professionals.

The article, "Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association," is in press with the Journal of Clinical Lipidology and can be accessed through the journal or on the NLA website.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.